Ongoing clinical trials testing immunotherapeutic agents in BCC patients
| Agent | Phase | Condition | Intervention | Status | ClinicalTrials.gov ID |
|---|---|---|---|---|---|
| Talimogene Laherparepvec | I | Non-melanoma Skin Cancer | Evaluation of the mechanism of action of talimogene laherparepvec (T-VEC) in patients with locally advanced non-melanoma skin cancer | Not yet recruiting | NCT03458117 |
| Basal Cell Carcinoma | |||||
| Squamous Cell Carcinoma Cutaneous Lymphoma | |||||
| Merkel Cell Carcinoma | |||||
| ASN-002 | I/II | Basal Cell Carcinoma in Basal Cell Nevus Syndrome | Study of ASN-002 to Treat Basal Cell Carcinomas in Individuals with Basal Cell Nevus Syndrome | Not yet recruiting | NCT03208296 |
| REGN2810 | II | Basal Cell Carcinoma | Anti-PD-1 in Patients with Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy | Recruiting | NCT03132636 |
| Nivolumab + Talimogene Laherparepvec | II | Refractory Lymphomas Advanced or Refractory Non-melanoma Skin Cancers | Talimogene Laherparepvec and Nivolumab in Treating Patients with Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | Recruiting | NCT02978625 |
| Pembrolizumab +/− Vismodegib | II | Skin Basal Cell Carcinoma | Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer | Active, not recruiting | NCT02690948 |
| ASN-002 +/− 5-FU | I/II | Basal Cell Nevus Syndrome Skin Neoplasm Nodular Basal Cell Carcinoma of Skin | A Study of the Efficacy and Safety of ASN-002 in Adult Patients with Low-risk Nodular Basal Cell Carcinoma | Recruiting | NCT02550678 |